Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119071002 | 11907100 | 2 | F | 2001 | 20160826 | 20160111 | 20160826 | EXP | GB-BRISTOL-MYERS SQUIBB COMPANY-11714169 | BRISTOL MYERS SQUIBB | 36.90 | YR | F | Y | 61.00000 | KG | 20160826 | OT | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119071002 | 11907100 | 1 | PS | ZERIT | STAVUDINE | 1 | Oral | 40 MG, BID | Y | 20412 | 40 | MG | BID | ||||||
| 119071002 | 11907100 | 2 | SS | VIDEX | DIDANOSINE | 1 | Oral | 200 MG, BID | 0 | 200 | MG | BID | |||||||
| 119071002 | 11907100 | 3 | SS | ABACAVIR. | ABACAVIR | 1 | Oral | 300 MG, BID | 0 | 300 | MG | BID | |||||||
| 119071002 | 11907100 | 4 | SS | ZIDOVUDINE. | ZIDOVUDINE | 1 | Oral | 250 MG, BID | 0 | 250 | MG | BID | |||||||
| 119071002 | 11907100 | 5 | SS | NEVIRAPINE. | NEVIRAPINE | 1 | Oral | 200 MG, QD | 0 | 200 | MG | QD | |||||||
| 119071002 | 11907100 | 6 | C | FOLIC ACID. | FOLIC ACID | 1 | Unknown | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 119071002 | 11907100 | 7 | C | SEPTRIN | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Unknown | 960 MG, QD | U | 0 | 960 | MG | QD | ||||||
| 119071002 | 11907100 | 8 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | Unknown | 1 DF, QD | U | 0 | 1 | DF | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 119071002 | 11907100 | 1 | HIV infection |
| 119071002 | 11907100 | 2 | HIV infection |
| 119071002 | 11907100 | 3 | HIV infection |
| 119071002 | 11907100 | 4 | HIV infection |
| 119071002 | 11907100 | 5 | HIV infection |
| 119071002 | 11907100 | 6 | Product used for unknown indication |
| 119071002 | 11907100 | 7 | Antifungal prophylaxis |
| 119071002 | 11907100 | 8 | Anaemia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 119071002 | 11907100 | HO |
| 119071002 | 11907100 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 119071002 | 11907100 | Caesarean section | |
| 119071002 | 11907100 | Insulin resistance | |
| 119071002 | 11907100 | Lipodystrophy acquired | |
| 119071002 | 11907100 | Live birth | |
| 119071002 | 11907100 | Pregnancy | |
| 119071002 | 11907100 | Thrombocytopenia | |
| 119071002 | 11907100 | Vaginal haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 119071002 | 11907100 | 1 | 199706 | 20010501 | 0 | |
| 119071002 | 11907100 | 2 | 199906 | 0 | ||
| 119071002 | 11907100 | 3 | 200103 | 0 | ||
| 119071002 | 11907100 | 4 | 20010501 | 0 | ||
| 119071002 | 11907100 | 5 | 199906 | 0 |